

**P.E.I. Pharmacare
Bulletin****Issue (2018-7)****November 13, 2018****NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY**
(Effective Date: November 26, 2018)

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
Infliximab	<u>Renflexis</u>	100 mg	Vial	02470373	MER
Criteria	For the treatment of ankylosing spondylitis, crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. Please see criteria for each condition in the PEI Pharmacare Formulary under Ankylosing Spondylitis Biologic Agents, Crohn's Disease Biologic Agents, Plaque Psoriasis Biologic Agents, Psoriatic Arthritis Biologic Agents, Rheumatoid Arthritis Biologic Agents and Ulcerative Colitis Biologic Agents at https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf				
Program Eligibility	High Cost Drug Program, Catastrophic Drug Program				
Insulin Degludec	<u>Tresiba</u>	100 unit/ml 200 unit/ml	Insulin Pen Insulin Pen	02467879 02467887	NNO
Criteria	Open benefit				
Program Eligibility	Diabetes Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Catastrophic Drug Program				